Press release

THIS PRESS RELEASE IS RESTRICTED AND IS NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY AND WHETHER IN WHOLE OR IN PART, INTO OR IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR IN ANY OTHER JURISDICTION IN VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

Avantium announces the successful completion of its €55 million equity raise

AMSTERDAM, 11 November 2026, 08:00 hrs CET – Avantium N.V. (the Company, Avantium or the Group[1]) today announces the successful completion of its fully committed and underwritten rights offering, raising gross proceeds of approximately €55.45 million.

- **The successful Offering provides Avantium with the funding to execute the next phase of its strategy, including the ramp-up of the FDCA Flagship Plant, first commercial deliveries and further development of its licensing business**
- **Gross proceeds from the Offering amount to approximately €55.45 million, resulting in the issue of 33,608,956 new ordinary shares at an Issue Price of €1.65 per Offer Share**
- **At the end of the Exercise Period on 10 November 2026, 28,817,796 Offer Shares were subscribed for through the exercise of Rights, representing a take-up rate of 85.7%**
- **The Rump Offering was fully subscribed**

Tom van Aken, Chief Executive Officer of Avantium, commented: "The successful completion of this Rights Offering is an important step forward for Avantium. We are grateful for the strong support from our shareholders, new investors and public partners, and for the confidence they have shown in our strategy.

With the first FDCA successfully produced at our Flagship Plant and this financing secured, our focus is firmly on what comes next: preparing for first commercial product deliveries from our FDCA Flagship Plant and accelerating our commercial and licensing activities. The funding puts us in a stronger position to execute our business plan. We have reached important milestones this year, and we are now focused on building on that momentum and translating our progress into commercial growth. Our ambition is clear: to scale FDCA and PEF globally through our Flagship Plant and our licensing business."

1 For definitions of capitalized terms, please refer to the Prospectus

Results of the Rights Offering

- The final gross proceeds of the Offering amount to approximately €55.45 million, corresponding to the issuance of 33,608,956 new ordinary shares at an issue price of €1.65 per Offer Share
- At the end of the Exercise Period on 10 November 2026, holders of Rights had exercised Rights for 28,817,796 Offer Shares, representing a take-up rate of 85.7%
- In addition, Excess Applications were received for 4,381,042 Offer Shares
- Following the Exercise Period, 4,791,160 Offer Shares that had not been subscribed for through the exercise of Rights were offered in the Rump Offering. The Rump Offering of 4,791,160 Rump Shares was fully subscribed
- The Rump Offering was oversubscribed and the available Rump Shares were allocated in accordance with the allocation principles described in the Prospectus
- Following completion of the Rights Offering and the Rump Offering, the Cornerstone Investors were allocated 4,303,029 Offer Shares through the exercise of their Rights and/or in the Rump Offering, representing an aggregate amount of approximately €7.10 million

Share capital after the Offering

A total of 33,608,956 new ordinary shares will be issued under the Offering, representing a dilution of 57.3%. Following settlement of the Offering, Avantium's issued share capital will comprise 59,357,593 ordinary shares, which includes 274,355 shares under the settlement of certain fees payable.

Settlement and delivery of the Offer Shares and commencement of trading in these shares on Euronext Amsterdam and Euronext Brussels are expected to take place at 09:00 CET on 13 November 2026.

Use of proceeds

The net proceeds of the Offering are expected to amount to approximately €50 million after deduction of approximately €5.0 million in transaction expenses.

Avantium intends to use the proceeds primarily to fund operating expenses and working capital requirements for its FDCA and PEF business, including the ramp-up of the FDCA Flagship Plant, and investments in commercial, technology and engineering activities supporting the commercialization of FDCA and PEF and the licensing of its YXY® Technology. The proceeds will also be used to fund general corporate expenses, support the execution of the Company's strategic portfolio review and fund financing costs and forecasted capital expenditure.

The Offering is expected to remedy the working capital shortfall identified in the Prospectus and provide sufficient working capital for at least 12 months following the date of the Prospectus. It also supports Avantium's ambition of reaching cumulative Group-level EBITDA break-even from December 2027 onwards, subject to the assumptions and risks described in the Prospectus.

Advisors

ABN AMRO Bank N.V. (in cooperation with ODDO BHF SCA), BNP PARIBAS and Stifel Europe Securities SAS acted as Joint Global Coordinators.

Invest-NL Capital N.V., together with the Joint Global Coordinators, acted as Underwriters.

ABN AMRO Bank N.V. acts as the Subscription, Listing and Paying Agent for the Offering.

Point Partners B.V. acted as advisor to the Company.

Availability of the Prospectus

The Offering has been made only by means of the Prospectus, approved by, and filed with, the AFM on 27 October 2026 as competent authority under the Prospectus Regulation. The Prospectus has been notified to the Belgian Financial Services and Markets Authority for passporting in accordance with article 25 of the Prospectus Regulation. The Prospectus is available electronically, free of charge, via the website of the Company https://newsroom.avantium.com/rights-offering-2026 and the AFM website (https://www.afm.nl/nl-nl/sector/registers/meldingenregisters/goedgekeurde-prospectussen), subject to securities law restrictions in certain jurisdictions.

About Avantium

Avantium is a pioneering commercial-stage company focused on renewable and circular polymer materials. Avantium develops and commercializes technologies for the production of high-performance materials based on sustainable carbon feedstocks. Its proprietary YXY® Technology catalytically converts plant-based sugars into furandicarboxylic acid (FDCA), the key building block for polyethylene furanoate (PEF), a plant-based, high-performance and circular polymer marketed under the brand name releaf®. Avantium has successfully demonstrated its YXY® Technology at pilot scale in Geleen, the Netherlands, and has produced the first FDCA at its Flagship Plant in Delfzijl, the world's first commercial-scale FDCA production facility. The company is currently progressing the start-up and commercialization of FDCA and PEF while pursuing a licensing strategy to enable the global deployment of FDCA production capacity. Through partnerships across the value chain, Avantium aims to accelerate the adoption of FDCA and PEF and contribute to a circular, fossil-free plastics economy.

Avantium's shares are listed on Euronext Amsterdam and Euronext Brussels (symbol: AVTX). Avantium is included in the Euronext Amsterdam SmallCap Index (AScX). Its offices and headquarters are in Amsterdam, the Netherlands.

This press release by Avantium N.V. contains information that qualifies as inside information within the meaning of section 7(1) of Regulation (EU) No 596/2014 on market abuse.

Forward-looking information / disclaimer

This press release may include forward-looking statements. Other than reported financial results and historical information, all statements included in this press release, including, without limitation, those regarding our financial position, business strategy and management plans and objectives for future operations, are forward-looking statements. These forward-looking statements are based on our current expectations and projections about future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements. Many of these risks and uncertainties relate to factors that are beyond Avantium's ability to control or estimate precisely, such as future market conditions, the behaviour of other market participants and the actions of governmental regulators. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release and are subject to change without notice. Other than as required by applicable law or the applicable rules of any exchange on which our securities may be traded, we have no intention or obligation to update forward-looking statements.

Any securities mentioned herein are not and will not be registered under the U.S. Securities Act of 1933, as amended (the **Securities Act**), and may not be offered or sold in the United States absent registration or unless pursuant to an applicable exemption from the registration requirements of the Securities Act. The Company has no intention to register any part of the offering in the United States or make a public offering of securities in the United States.

For more information:
Caroline van Reedt Dortland, Director Communications
+31-20-5860110 / +31-613400179
mediarelations@avantium.com

Aarne Luten, Director Investor Relations
+31-625687714
ir@avantium.com

DISCLAIMER

These materials are not for release, distribution or publication, whether directly or indirectly and whether in whole or in part, in or into the United States, Canada, Australia or Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.

These materials are for information purposes only and are not intended to constitute, and should not be construed as, an offer to sell or a solicitation of any offer to buy the securities of Avantium N.V. (the Company, and such securities, the Securities) in the United States, Canada, Australia or Japan or in any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of such jurisdiction.

This announcement is not for publication or distribution, directly or indirectly, in or into the United States. This announcement is not an offer of securities for sale into the United States. The Securities

have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States. No public offering of securities is being made in the United States.

The Company has not authorised any offer to the public of Securities in any Member State of the European Economic Area other than the Netherlands and Belgium. With respect to any Member State of the European Economic Area, other than the Netherlands and Belgium (each a **Relevant Member State**), no action has been undertaken or will be undertaken to make an offer to the public of Securities requiring publication of a prospectus in any Relevant Member State. As a result, the Securities may only be offered in Relevant Member States (i) to any legal entity which is a qualified investor as defined in section 2(e) of the Prospectus Regulation; or (ii) in any other circumstances falling within section 1(4) of the Prospectus Regulation. For the purpose of this paragraph, the expression "offer of securities to the public" means the communication in any form and by any means of sufficient information on the terms of the offer and the Securities to be offered so as to enable the investor to decide to purchase or subscribe for the Securities and the expression "Prospectus Regulation" means Regulation (EU) 2017/1129 and includes any relevant delegated regulations.

No Securities have been offered or will be offered to the public in the United Kingdom, except that the Securities may be offered to the public in the United Kingdom at any time: (i) to any qualified investor as defined in paragraph 15 of Schedule 1 of the POATR; (ii) to fewer than 150 persons (other than qualified investors as defined in paragraph 15 of Schedule 1 of the POATR); or (iii) in any other circumstances falling within Part 1 of Schedule 1 of the POATR. For the purpose of this paragraph, the expression "offer to the public" in relation to the Securities in the United Kingdom means the communication to any person which presents sufficient information on (a) the Securities to be offered and (b) the terms on which they are to be offered, to enable an investor to decide to buy or subscribe for the Securities, and the expression "POATR" means the Public Offers and Admissions to Trading Regulations 2024. No action has been taken by the Company that would permit an offer of Securities or the possession or distribution of these materials or any other offering or publicity material relating to such Securities in any jurisdiction where action for that purpose is required.

The release, publication or distribution of these materials in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which they are released, published or distributed, should inform themselves about, and observe, such restrictions.

These materials may include statements, including the Company's financial and operational medium-term objectives that are, or may be deemed to be, "forward-looking statements". These forward-looking statements may be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "plans", "projects", "anticipates", "expects", "intends", "may", "will" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. Forward-looking statements may and often do differ materially from actual results. Any forward-looking statements reflect the Company's current view with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to the Company's business,

results of operations, financial position, liquidity, prospects, growth or strategies. Forward-looking statements speak only as of the date they are made.

Each of the Company, as well as the Underwriters, including Joint Global Coordinators and their respective affiliates expressly disclaims any obligation or undertaking to update, review or revise any forward-looking statement contained in these materials whether as a result of new information, future developments or otherwise.

The Joint Global Coordinators are acting exclusively for the Company and no one else in connection with any offering of Securities. They will not regard any other person as their respective clients in relation to any offering of Securities and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients nor for providing advice in relation to any offering of Securities, the contents of these materials or any transaction, arrangement or other matter referred to herein. None of the Underwriters or any of their respective subsidiary undertakings, affiliates or any of their respective directors, officers, employees, advisers, agents, alliance partners or any other entity or person accepts any responsibility or liability whatsoever for, or makes any representation, warranty or undertaking, express or implied, as to the truth, accuracy, completeness or fairness of the information or opinions in these materials (or whether any information has been omitted from these materials) or any other information relating to the group, its subsidiaries or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of these materials or its contents or otherwise arising in connection therewith. Accordingly, the Underwriters disclaim, to the fullest extent permitted by applicable law, all and any liability, whether arising in tort or contract or that they might otherwise be found to have in respect of these materials and/or any such statement.

This announcement does not constitute a prospectus. The Offering has been made solely on the basis of the Prospectus approved by the AFM on 27 October 2026 which is available on the website of the Company.

In connection with the Offering, each of the Underwriters and any of their affiliates, may take up a portion of the Securities in the Offering as a principal position and, in that capacity, may retain, purchase, sell, offer to sell for its own account such Securities and other securities of the Company or related investments in connection with the Offering or otherwise. In addition, each of the Joint Global Coordinators and any of their affiliates may enter into financing arrangements (including swaps or contracts for differences) with investors in connection with which each of the Joint Global Coordinators and any of their affiliates may from time to time acquire, hold or dispose of Securities. None of the Joint Global Coordinators or their affiliates intends to disclose the extent of any such investment or transactions otherwise than in accordance with any legal or regulatory obligations to do so.

Information to distributors

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended (MiFID II); (b) sections 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing

measures (together, the **MiFID II Product Governance Requirements**), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the Securities subject to the Offering have been subject to a product approval process, which has determined that such Securities are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the **Target Market Assessment**).

Notwithstanding the Target Market Assessment, "distributors" (for the purposes of the MiFID II Product Governance Requirements) should note that: the price of the Securities may decline and investors could lose all or part of their investment; the Securities offer no guaranteed income and no capital protection; and an investment in the Securities is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Offering.

For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Securities.

Each distributor is responsible for undertaking its own target market assessment in respect of the Securities and determining appropriate distribution channels.